Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.59 |
| ▸ | WNT3A | P56704 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025406 | 1.00 | HDAC6 (0.66) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL4541627 | 0.98 | HDAC6 (0.64) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL6976349 | 0.89 | HTT (0.57) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| SCHEMBL476588 | 0.86 | AR (0.52) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL4541624 | 0.84 | AR (0.51) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| SCHEMBL5946 | 0.84 | RAB9A (0.71) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| SCHEMBL5131245 | 0.83 | HDAC6 (0.59) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| Methylamine SCHEMBL3153881 | 0.83 | RAB9A (0.65) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| SCHEMBL1232537 | 0.82 | HDAC6 (0.57) | HDAC6RAB9AHTTSMN1; SMN2KDM4E | |
| SCHEMBL5777206 | 0.82 | HDAC6 (0.66) | HDAC6RAB9AHTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083838-A1 | Adjuvant Composition Comprising STING Agonists | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-03-26 | — | — | US | claimed |
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4651877-A1 | INHIBITORS OF ACTIVIN RECEPTOR TYPE 1 (ACVR1) AND ACTIVIN RECEPTOR LIKE TYPE 1 (ACVRL1), AND METHODS USING SAME | Baylor College of Medicine (US) | 2025-11-26 | — | — | EP | claimed |
| WO-2024155715-A1 | INHIBITORS OF ACTIVIN RECEPTOR TYPE 1 (ACVR1) AND ACTIVIN RECEPTOR LIKE TYPE 1 (ACVRL1), AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-25 | — | — | WO | claimed |
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | claimed |
| CN-118146163-A | Benzimidazole derivative and preparation method thereof | 雅安职业技术学院 | 2024-06-07 | — | — | CN | claimed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | claimed |
| CN-113166156-B | Tyrosine kinase inhibitors, compositions and methods | 贝达药业股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | claimed |
| EP-4225739-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | claimed |
| JP-2005506349-A | — | — | 2005-03-03 | — | — | JP | claimed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | claimed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004093873-A1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-`4,5!-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-04 | — | — | WO | claimed |
| EP-1435947-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2004035548-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | claimed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| WO-2003099811-A1 | KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | claimed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | claimed |
| EP-0656002-B1 | 3-OXO-PYRIDO(1,2-A -)BENZIMIDAZOLE-4-CARBOXYL AND 4-OXO-AZEPINO(1,2-A -)BENZIMIDAZOLE-5-CARBOXYL DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | MCNEILAB INC (US) | 2000-11-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083838-A1 | Adjuvant Composition Comprising STING Agonists | STING1, CGAS, IFNAR1 | HDAC6 4723/4885RAB9A 1959/4885HTT 4647/4885 |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | HDAC6 599/4885RAB9A 3526/4885HTT 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.